Tisotumab vedotin is an antibody-drug conjugate (ADC) targeting tissue factor (TF), consisting of the fully human monoclonal antibody (TF-011) conjugated with monomethyl auristatin E (MMAE). It exhibits significant antitumor activity and is suitable for research on the treatment of advanced or metastatic solid tumors.

Tisotumab vedotin induces immunogenic cell death in tumor cells expressing tissue factor (TF) and promotes the release of endoplasmic reticulum stress markers, ATP, and high-mobility group box 1 (HMGB1) [1].
Tisotumab vedotin exerts antitumor activity through MMAE-mediated cytotoxicity, Fc-mediated antibody-dependent cellular phagocytosis (ADCP), and Fab-mediated inhibition of protease-activated receptor 2 (PAR‑2) signaling [2].

Tisotumab vedotin can induce immunogenic cell death of tumor cells, and promote the activation and recruitment of F4/80+ and CD11c+ innate immune cells to the xenograft tumor site [1].
Tisotumab vedotin (2 mg/kg, once daily for 25 consecutive days) exhibited antitumor activity in a mouse model of pancreatic cancer [4].

Human

Monoclonal, ADC

MMAE